On Wednesday, Novo Nordisk announced its latest efforts to optimize its experimental obesity drug, CagriSema, by focusing on dose escalation and trial duration. This follows December’s data release that failed to meet market expectations, causing a significant drop in the company’s share value.
About the Author
